Evotec在2025年取得了强劲的成果,收入增加,EBITDA和临床输油管道取得进展。 Evotec posted strong 2025 results with rising revenue, EBITDA, and clinical pipeline progress.

Evotec SE报告说,2025年头九个月的财政和业务业绩良好,突出显示其战略目标继续取得进展。 Evotec SE reported strong financial and operational performance for the first nine months of 2025, highlighting continued progress on its strategic goals. 该公司在药物发现和开发方面取得了重大里程碑,多个方案进入临床阶段。 The company achieved significant milestones in drug discovery and development, with multiple programs advancing into clinical stages. 在扩大伙伴关系和成功完成项目推动下,投资、技术和企业发展司的收入和经调整的收入逐年增加。 Revenue and adjusted EBITDA increased year-over-year, driven by expanded partnerships and successful project completions. Evotec还通过新的协作和内部创新加强了其管道增长,保持了提供变革疗法的使命的势头。 Evotec also reinforced its pipeline growth through new collaborations and internal innovation, maintaining momentum in its mission to deliver transformative therapies.